POLYCYTHEMIA VERA
Clinical trials for POLYCYTHEMIA VERA explained in plain language.
Never miss a new study
Get alerted when new POLYCYTHEMIA VERA trials appear
Sign up with your email to follow new studies for POLYCYTHEMIA VERA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo study halted early: hope for advanced blood cancer patients
Disease control TerminatedThis study tested a combination of two drugs, ruxolitinib and CPX-351, in people with advanced myeloproliferative neoplasms (MPN), a type of blood cancer that has progressed. The goal was to find the best dose and see if the combination worked better than CPX-351 alone. Only 12 p…
Matched conditions: POLYCYTHEMIA VERA
Phase: PHASE1, PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Blood markers may predict drug resistance in rare blood cancer
Knowledge-focused TerminatedThis study looked at whether two simple blood test results—hemoglobin and red blood cell distribution width—can predict if a person with polycythemia vera will stop responding to the drug hydroxyurea. Researchers used a computer model to identify these markers and then tested the…
Matched conditions: POLYCYTHEMIA VERA
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated May 15, 2026 11:57 UTC